Related Experiment Videos
Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development
A H Brandenburg1, H J Neijens, A D Osterhaus
1Institute of Virology, Erasmus University, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
Insights
Developing a safe and effective respiratory syncytial virus (RSV) vaccine is challenging. Live attenuated vaccines show promise for infants, while subunit vaccines are promising for older individuals at risk.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Respiratory syncytial virus (RSV) is a leading cause of severe infant respiratory illness.
- RSV also causes significant illness in older children and adults with risk factors.
- Past RSV vaccine development faced challenges, including issues with formalin-inactivated RSV and age-specific administration.
Purpose of the Study:
- To review the challenges and promising strategies for respiratory syncytial virus (RSV) vaccine development.
- To evaluate the potential of different vaccine platforms for various age groups.
Main Methods:
- Review of existing literature on RSV vaccine development.
- Analysis of vaccine-induced immune responses and safety data.
- Evaluation of different vaccine types, including live attenuated and subunit vaccines.
Main Results:
- Live attenuated vaccines are considered most promising for infants, potentially avoiding enhanced pathology.
- Achieving the right balance between attenuation and immunogenicity is critical for infant vaccines.
- Subunit vaccines show promise for older individuals and those with underlying risk factors.
Conclusions:
- RSV vaccine development requires careful consideration of vaccine platform and target population.
- Live attenuated vaccines offer potential for infant immunization.
- Subunit vaccines represent a promising approach for older, at-risk populations.
Abstract:
Respiratory syncytial virus (RSV) infection is the most prevalent cause of severe respiratory disease in infants. It also causes considerable morbidity in older children and adults with underlying risk factors. RSV vaccine development has been complicated by the need to administer the vaccine at a very young age and by enhanced disease observed after vaccination with formalin inactivated RSV. For infants live attenuated vaccines, which may not be expected to predispose for vaccine induced enhanced pathology, hold the greatest promise. However, the balance between attenuation and immunogenicity appears to be delicate. For older risk groups, results with subunit vaccines are most promising.